Impact of atomoxetine on health-related quality of life and functional status in patients with ADHD

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 4, 2006, Pages 379-390

  Matza, Louis S ^a   Stoeckl, Maria N ^a   Shorr, Jodi M ^a   Johnston, Joseph A ^b  

^a UBC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

ADHD; Atomoxetine; Attention deficit hyperactivity disorder; Health related quality of life

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PLACEBO; PSYCHOSTIMULANT AGENT;

ACADEMIC ACHIEVEMENT; ATTENTION DEFICIT DISORDER; CHILD BEHAVIOR; CLINICAL TRIAL; DRUG DOSE REGIMEN; FAMILY FUNCTIONING; FUNCTIONAL STATUS; HUMAN; MEDLINE; MENTAL HEALTH; OCCUPATION; PARENTAL BEHAVIOR; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; REVIEW; SELF CONTROL; SELF ESTEEM; SOCIAL ASPECT; SYMPTOM; TREATMENT OUTCOME; WORK CAPACITY;

EID: 33748098895     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.4.379     Document Type: Review

References (78)

1. Revicki DA, Osoba D, Fairclough D et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual. Life Res. 9, 887 - 900 (2000).
2. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of fife. Ann. Intern. Med. 118, 622 - 629 (1993).
3. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 2, 113 - 127 (1999).
4. Matza LS, Swensen AR, Flood EM, Secnik K, Leidy NK. Assessment of health-related quality of life in children: a review of conceptual, methodological, and regulatory issues. Value Health 7, 79 - 92 (2004).
5. Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol, Assess. 5, 1 - 157 (2001).
6. Clauser SB, Bierman AS. Significance of functional status data for payment and quality. Health Care Financ. Rev. 24, 1 - 12 (2003).
7. Patrick DL, Chiang YP. Measurement of health outcomes in treatment effectiveness evaluations: Conceptual and methodological challenges. Med. Care 38, 14 - 25 (2000).
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. American Psychiatric Press, Washington, DC, USA (2000).
9. Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 2nd Edition. Guilford Press, New York, USA (1998).
10. Barkley RA, DuPaul GJ, McMurray MB. Comprehensive evaluation of attention deficit disorder with and without hyperactivity as defined by research criteria. J. Consult. Clin. Pychol. 58, 775 - 789 (1990).
11. Barkley RA, Anastopoulos AD, Guevremont DC, Fletcher KE. Adolescents with ADHD: patterns of behavioral adjustment, academic functioning, and treatment utilization. J. Am. Acad. Child. Adolesc. Psych. 30, 752 - 761 (1991).
12. Brod M, Perwien A, Adler L, Spencer T, Johnston J. Conceptualization and assessment of quality of life for adults with attention-deficit/ hyperactivity disorder. Primary Psychiatry 12, 58 - 64 (2005).
13. Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 116, E364 - E369 (2005).
14. Hinshaw RD, Melnick SM. Peer relationship in boys with attention deficit hyperactivity disorder with and without comorbid aggression. Dev. Psychopathol. 7, 627 - 647 (1995).
15. Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 114, E541 - E547 (2004).
16. Matza LS, Rentz AM, Secnik K et al. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J. Dev. Behav. Pediatr. 25, 166 - 174 (2004).
17. Sawyer MG, Whaites L, Rey JM, Hazell PL, Graetz BW, Baghurst P. Health-related quality of life of children and adolescents with mental disorders. J. Am. Acad. Child. Adolesc. Psych. 41, 530 - 537 (2002).
18. Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit/hyperactivity disorder in children. J. Clin. Psychiatry 63, 16 - 22 (2002).
19. Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin. Ther. 25, 3065 - 3083 (2003).
20. Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 24, 1020 - 1036 (2004).
21. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention- deficit/hyperactivity disorder. Am. J. Health Syst. Pharm. 61, 2391 - 2399 (2004).
22. Simpson D, Plosker GL. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs 18, 397 - 401 (2004).
23. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J. Clin. Psychiatry 63, 50 - 55 (2002).
24. Saylor K, Buermeyer C, Sutton V, Faries D, Khan S, Schuh K. An update on the responsiveness and psychometric properties of the life participation scale for ADHD: an adaptive change assessment instrument. Poster presented at the 45th Annual Meeting of New Clinical Drug Evaluation Unit (NCDEU), June 6-9, Boca Raton, FL, USA (2005).
25. Perwien AR, Faries DE, Kratochvil CJ, Sumner CR, Kelsey DK, Allen AJ. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J. Dev. Behav. Pediatr. 25, 264 - 271 (2004).
26. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. Guilford Press, New York, USA (1998).
27. Gianarris WJ, Golden CJ, Greene L. The Conners' Parent Rating Scales: a critical review of the literature. Clin. Pychol. Rev. 21, 1061 - 1093 (2001).
28. Matza LS, Secnik K, Rentz AM et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. Qual. Life Res. 14, 735 - 747 (2005).
29. Secnik K, Matza LS, Cottrell S, Edgell E, Tilden D, Mannix S. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med. Decis. Making 25, 56 - 70 (2005).
30. Feeny D, Barr RD, Furlong W, Torrance GW, Weitzman S. Quality of life of the treatment process in pediatric oncology: an approach to measurement. In: Effect of Cancer on Quality of Life. Osaba D (Ed.) CRC Press, Boca Raton, FL, USA (1991).
31. Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev. Pharmacoeconomics Res. 2, 99 - 108 (2002).
32. Landgraf JM, Abetz LN, Ware JE. The CHQ User's Manual. HealthAct, Boston, MA, USA (1999).
33. Landgraf JM, Maunsell E, Speechley KN et al. Canadian-French, German, and UK versions ofthe Child Health Questionnaire: methodology and preliminary item scaling results. Qual. Life Res. 7, 433 - 445 (1998).
34. Rentz AM, Matza LS, Secnik K, Swensen AR, Revicki DA. Psychometric validation of the Child Health Questionnaire (CHQ) in a sample of children and adolescents with attention-seficit/hyperactivity disorder. Qual. Life Res. 14, 719 - 734 (2005).
35. Waters E, Salmon L, Wake M. The parent-form Child Health Questionnaire in Australia: comparison of reliability, validity, structure, and norms. J. Pediatr. Psychol. 25, 381 - 391 (2000).
36. Waters E, Salmon L, Wake M, Hesketh K, Wright M. The Child Health Questionnaire in Australia: reliability, validity and population means. Aust. NZ J. Public Health 24, 207 - 210 (2000).
37. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrcs 108, E83 (2001).
38. Perwien AR, Faries D, Kratochvil C. Long-term effects of atomoxetine on health-realted quality of life. Poster presented at: American Academy of Child and Adolescent Psychiatry's (AACAP) 51st Annual Meeting, Miami Beach, FL, USA, October 14 - 19 (2003).
39. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30, 473 - 483 (1992).
40. Ware JE, Snow KK, Kosinski MK, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. The Health Institute, New England Medical Center, Boston, MA, USA (1993).
41. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med. Care 32, 40 - 66 (1994).
42. Adler L, Kelsey D, Dietrich AP et al. Quality-of-life assessment in atomoxetine-treated adult ADHD patients. Poster presented at: 157th Annual Meeting of the American Psychiatric Association. New York, NY, USA, May 1 - 6 (2004).
43. Dupuy HJ. The Psychological General wellbeing (PGWB) Index. In: Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Wenger NK, Mattson ME, Furberg CD et al. (Eds). Le Jacq Publishing, Washington, DC, USA, 170 - 183 (1984).
44. Leonardson GR, Daniels MC, Ness FK et al. Validity and reliability of the general wellbeing schedule with northern plains American Indians diagnosed with type 2 diabetes mellitus. Pychol, Rep. 93, 49 - 58 (2003).
45. Revicki DA, Zodct MW, Joshua-Gotlib S, Levine D, Crawley JA. Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. Health Qual. Life Outcomes 1, 73 (2003).
46. Saylor KE, Buermeyer CM, Spencer TJ, Barkley RA. Adaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medication. J. Clin. Pychiatry 63, 23 - 28 (2002).
47. Landgraf JM, Rich M, Rappaport L. Measuring quality of life in children with attention-deficit/hyperactivity disorder and their families: development and evaluation of a new tool. Arch. Pediatr. Adolesc. Med. 156, 384 - 391 (2002).
48. Brod M, Johnston J, Able S, Swindle R. Adult ADHD Quality of Life: A new measure - the AAQOL. Poster presented at: American Academy of Child and Adelescent Psychiatry's (AACAP) 51st Annual Meeting. Washington, DC, USA, October 19 - 24 (2004).
49. Brod M, Johnston J, Able S, Swindle R. Validation of a quality-of-life measure for adult attention-deficit/hyperactivity disorder. Qual. Life Res. 15(1) 117 - 129 (2006).
50. Weiss M, Tannock R, Kratochvil C et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J. Am. Acad. Child. Adolesc. Psych. 44, 647 - 655 (2005).
51. DuPaul GJ, Rapport MD, Perriello LM. Teacher rating scales of academic skills: The development of the academic performance rating scale. School Psych. Rev. 20, 284 - 300 (1991).
52. Gresham FM, Eliot SN. Social Skills Rating System Manual. American Guidance Service, Circle Pines, MN, USA (1990).
53. Van der Oord S, Van der Meulen EM, Prins PJ, Oosterlaan J, Buitelaar JK, Emmelkamp PM. A psychometric evaluation of the social skills rating system in children with attention deficit hyperactivity disorder. Behav. Res. Ther. 43, 733 - 746 (2005).
54. Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am. J. Psychiatry 159, 1896 - 1901 (2002).
55. Kelsey DK, Sumner CR, Casat CD et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 114, E1 - E8 (2004).
56. Sutton V, Sumner C, Allen AJ, Feng W, Schuh K, Michelson D. Validity reliability, and responsiveness of the DPREMB-R scale for ADHD. Poster presented at: American Academy of Child and Adolescent Psychiatry's (AACAP) 51st Annual Meeting, Miami Beach, FL, USA, October 14 - 19 (2003).
57. Kelsey D, Sutton V, Lewis D, Schuh K, Sumner C, Quintana H. Morning-dosed versus evening-dosed atomoxetine for treating ADHD in children. Poster presented at: 158th Annual Meeting of the American Psychiatric Association. Atlanta, GA, USA, May 21 - 26 (2005).
58. Leon AC, Shear MK, Portera L, Klerman GL. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc. Psychiatry Pychiatr. Epidemiol. 27, 78-82 (1992).
59. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV, Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int. J. Psychiatry Med. 27, 93-105 (1997).
60. Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol. Psychiatry 53, 112-120 (2003).
61. Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J. Clin. Psychiatry 66, 294 - 299 (2005).
62. Torrance GW. Measurement of health state utilities for economic appraisal. J. Health Econ. 5, 1-30 (1986).
63. Torrance GW. Designing and conducting cost-utility analyses. In: Quality of life and Pharmacoeconomics in Clinical Trials. 2nd Edition. Spilker B (Ed.). Lippincott-Raven Publishers, Philadelphia, PA, USA (1996).
64. Detmar SB, Aaronson NK. Quality of life assessment in daily clinical oncology practice: a feasibility study. Eur. J. Cancer 34, 1181-1186 (1998).
65. Detmar SB, Muller MJ, Schornagel JH, Wever LDV. Aaronson NK. Health-related quality-of-life assessments and patient - physician communication: A randomized controlled trial. JAMA 288, 3027 - 3034 (2002).
66. Velikova G, Booth L, Smith AB et al. Measuring quality of life in routine oncology practice improves communication and patient wellbeing: A randomized controlled trial. J. Clin. Oncol. 22, 714 - 724 (2004).
67. Prasad S, Sonuga-Barke E, Poole L. Atomoxetine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: effects on broader efficacy. Oral presentation at: International Association for Child & Adolescent Psychiatry and Allied Professionals Annual Meeting. Berlin, Germany, August 22 - 26 (2004).
68. Ralston SJ, Lorenzo MJ. ADORE - Attention-deficit hyperactivity disorder observational research in europe. Eur. Child Adolesc. Psychiatry 13, I36 - I42 (2004).
69. Hechtman L, Greenfield B. Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatr. Drugs 5, 787 - 794 (2003).
70. Jensen P, Longer term effects of stimulant treatments for attention-deficit/hyperactivity disorder. J. Atten. Disord. 6, S45 - S56 (2002).
71. Connor DF, Edwards G, Fletcher KE, Baird J, Barkley RA, Steingard RJ. Correlates of comorbid psychopathology in children with ADHD. J. Am. Acad. Child. Adolesc. Psych. 42, 193 - 200 (2003).
72. Jensen PS, Hinshaw SP, Kraemer HC et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J. Am. Acad. Child. Adolesc. Psych. 40, 147 - 158 (2001).
73. Kadesjo B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J. Child Psychol. Psychiatry 42, 487 - 492 (2001).
74. Wilens TE, Biederman J, Brown S et al. Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD. J. Am. Acad. Child. Adolesc. Psych. 41, 262 - 268 (2002).
75. Abikoff H, McGough J, Vitiello B et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J. Am. Acad. Child. Adolesc. Psych. 44, 418 - 427 (2005).
76. Diamond IR, Tannock R, Schachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J. Am. Acad. Child. Adolesc. Psych. 38, 402 - 409 (1999).
77. Kratochvil CJ, Newcorn JH, Arnold LE et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J. Am. Acad. Child. Adolesc. Psych. 44, 915 - 924 (2005).
78. Moore JL, McAuley JW, Long L, Bornstein R. An evaluation of the effects of methylphenidate on outcomes in adult epilepsy patients. Epilepsy Behav. 3, 92 - 95 (2002).